Ambrx Biopharma Management

Management criteria checks 1/4

Ambrx Biopharma’s CEO is Dan O'Connor, appointed in Nov 2022, he has a tenure of less than a year. His total yearly compensation is US$1.0m, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. He directly owns 5.0% of the company’s shares, worth US$38.5m. The average tenure of the management team and the board of directors is less than a year and less than a year respectively.

Key information

Dan O'Connor

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage6.7%
CEO tenureless than a year
CEO ownership5.0%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates

Ambrx Biopharma (NASDAQ:AMAM) Is In A Good Position To Deliver On Growth Plans

May 25
Ambrx Biopharma (NASDAQ:AMAM) Is In A Good Position To Deliver On Growth Plans

Here's Why Ambrx Biopharma (NYSE:AMAM) Must Use Its Cash Wisely

Feb 06
Here's Why Ambrx Biopharma (NYSE:AMAM) Must Use Its Cash Wisely

Ambrx Biopharma: Some Promise, Much Uncertainty

Jan 17

Ambrx Biopharma receives NYSE notice for non-compliance

Dec 19

Ambrx to cut workforce, pause internal development of lead cancer drug candidate

Oct 18

Ambrx Biopharma GAAP EPS of -$0.19, revenue of $2.91M

Aug 29

Ambrx Biopharma to offer stocks up to $300M

Jul 29

CEO Compensation Analysis

How has Dan O'Connor's remuneration changed compared to Ambrx Biopharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$1mUS$69k

-US$78m

Compensation vs Market: Dan's total compensation ($USD1.03M) is below average for companies of similar size in the US market ($USD3.63M).

Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.


CEO

Dan O'Connor (57 yo)

less than a year

Tenure

US$1,034,168

Compensation

Mr. Daniel J. O'Connor, J.D., also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He serves as President at Ambrx Biopharma Inc. since...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel O'Connor
CEO, President & Directorless than a yearUS$1.03m4.98%
$ 38.5m
Sonja Nelson
Chief Financial Officer1.9yrsUS$1.73m1.81%
$ 14.0m
Andrew Aromando
Chief Operating Officerless than a yearno datano data
Ying Buechler
Chief Technology Officer1.3yrsno datano data
Shawn Zhang
Chief Scientific Officer & GM of Chinaless than a yearno datano data
Sandra Aung
Chief Clinical Officerless than a yearno datano data

0.5yrs

Average Tenure

53yo

Average Age

Experienced Management: AMAM's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Daniel O'Connor
CEO, President & Directorless than a yearUS$1.03m4.98%
$ 38.5m
Paul Maier
Independent Director1.3yrsUS$268.55k0%
$ 0
Peter Schultz
Member of Scientific Advisory Boardno datano datano data
Stephen Glover
Chairman of the Boardno datano datano data
Stuart Lutzker
Member of Scientific Advisory Boardno datano datano data
Melissa Starovasnik
Member of Scientific Advisory Boardno datano datano data
Jakob Dupont
Member of Scientific Advisory Boardno datano datano data
Xiaowei Chang
Independent Director7.9yrsUS$4.13kno data
Kate Hermans
Independent Directorless than a yearUS$555.41k0%
$ 0
Luisa Salter-Cid
Member of Scientific Advisory Boardno datano datano data
Janet Loesberg
Independent Directorless than a yearUS$156.12k0%
$ 0

0.9yrs

Average Tenure

57.5yo

Average Age

Experienced Board: AMAM's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.